Basel, July 2, 2026 – Novartis today announced that the European Commission (EC) has approved Itvisma ® (onasemnogene ...

Designation based on clinical evidence supporting potential of ianalumab in Sjögren’s disease, including phase III trials1 Distinction expedites development and review of treatments for serious ...

About Novartis Immunology At Novartis, we’re advancing bold science for autoimmune diseases, where meaningful therapeutic progress has long stalled. With a growing legacy of first-in-class innovation ...

Our work is powered by a toolkit of five R&D approaches – two established platforms (chemistry and biotherapeutics) plus three advanced platforms (xRNA, radioligand therapy and gene and cell therapy) ...

The need to improve access to medicines remains one of the world’s greatest healthcare challenges. Through the Novartis Access Principles, we are committed to expanding access to our medicines to ...

Transforming the treatment and healthcare system landscape using early interventions, pioneering treatments, and innovative partnerships to avoid preventable mortality from cardiovascular disease (CVD ...

With new tools and approaches comes broader opportunity to benefit patients. Cardiovascular and metabolic diseases are responsible for nearly 18 million deaths worldwide each year and represent a huge ...

Continuously rising dividend since 1996 Shareholders approved the 29th consecutive dividend increase per share since the creation of Novartis in 1996, with an increase of 5.7% to CHF 3.70 per share ...

The purpose of this study is to characterize the effect on dengue viral load, fever clearance time as well as on clinical signs and symptoms with the treatment of EYU688 compared with placebo in ...

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

Disclaimer: The information provided on this website does not constitute investment advice, or an offer of, or an invitation or solicitation by, or on behalf of, Novartis AG or any of its subsidiaries ...

Awareness and training programs are offered regularly in a range of formats, including awareness-building programs, e-training, face-to-face programs, games and workshops. We provide extensive ...